K\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lar, \u00f6zellikle hedefe y\u00f6nelik kalp yetmezli\u011fi tedavileri<\/strong> s\u00f6z konusu oldu\u011funda, modern kardiyolojinin en heyecan verici ara\u00e7lar\u0131 aras\u0131nda yer al\u0131yor. Bu alanda son y\u0131llar\u0131n en \u00e7ok konu\u015fulan molek\u00fcllerinden biri de mavacamten<\/strong>. Obstr\u00fcktif hipertrofik kardiyomiyopati (HCM) tedavisinde oyunun kurallar\u0131n\u0131 de\u011fi\u015ftiren bu k\u00fc\u00e7\u00fck molek\u00fcl, kalp kas\u0131 h\u00fccrelerinin motor proteini olan kardiyak miyozini<\/strong> do\u011frudan hedef al\u0131yor ve a\u015f\u0131r\u0131 kas\u0131lmay\u0131 kontroll\u00fc bi\u00e7imde azalt\u0131yor (doi:10.1056\/NEJMoa2002329).<\/p>\n Mavacamten\u2019i \u00f6zel k\u0131lan nokta, klasik kalp yetmezli\u011fi ila\u00e7lar\u0131nda oldu\u011fu gibi yaln\u0131zca semptomlar\u0131 bask\u0131lamaya \u00e7al\u0131\u015fmamas\u0131. Bunun yerine, hastal\u0131\u011f\u0131n temel mekanizmas\u0131n\u0131 mod\u00fcle etmeye<\/strong> odaklan\u0131yor. Bu nedenle literat\u00fcrde, \u201chastal\u0131k mekanizmas\u0131n\u0131 hedefleyen ilk k\u00fc\u00e7\u00fck molek\u00fcl miyozin inhibit\u00f6rlerinden biri\u201d olarak tan\u0131mlan\u0131yor (doi:10.1161\/CIRCULATIONAHA.121.056323). Bu yakla\u015f\u0131m, kalp yetmezli\u011fine bak\u0131\u015f\u0131m\u0131z\u0131 semptom y\u00f6netiminden, molek\u00fcler d\u00fczeyde k\u00f6k neden m\u00fcdahalesine<\/strong> do\u011fru kayd\u0131r\u0131yor.<\/p>\n Hipertrofik kardiyomiyopati, kalp kas\u0131 duvarlar\u0131n\u0131n kal\u0131nla\u015ft\u0131\u011f\u0131, sol ventrik\u00fcl \u00e7\u0131k\u0131\u015f yolunun (LVOT) darald\u0131\u011f\u0131 ve sonu\u00e7ta kan\u0131n kalpten \u00e7\u0131kmakta zorland\u0131\u011f\u0131 bir hastal\u0131k. Bu tabloda \u00f6nemli sorunlardan biri, a\u015f\u0131r\u0131 miyozin\u2013aktin etkile\u015fimi<\/strong> ve artm\u0131\u015f kontraktilite. Yani kalp kas\u0131, adeta \u201cgere\u011finden fazla g\u00fc\u00e7l\u00fc ve sert\u201d kas\u0131l\u0131yor.<\/p>\n Mavacamten, kardiyak miyozinin ATPaz aktivitesini se\u00e7ici ve geri d\u00f6n\u00fc\u015f\u00fcml\u00fc olarak inhibe ederek<\/strong> bu a\u015f\u0131r\u0131 \u00e7apraz-k\u00f6pr\u00fc olu\u015fumunu azalt\u0131yor (doi:10.1161\/CIRCRESAHA.120.317105). Sonu\u00e7ta:<\/p>\n Bu y\u00f6n\u00fcyle mavacamten, beta bloker veya kalsiyum kanal blokerlerinden farkl\u0131 olarak, sinyal yolaklar\u0131n\u0131 de\u011fil do\u011frudan motor proteini hedefleyen k\u00fc\u00e7\u00fck molek\u00fcl tedavisi<\/strong> olarak \u00f6ne \u00e7\u0131k\u0131yor. Yani \u201cgaz pedal\u0131na giden sinyali\u201d k\u0131smak yerine, do\u011frudan \u201cmotorun g\u00fcc\u00fcn\u00fc\u201d ince ayarla d\u00fczenliyor.<\/p>\n Mavacamten\u2019in klinik etkinli\u011fi en net \u015fekilde EXPLORER-HCM<\/strong> faz 3 \u00e7al\u0131\u015fmas\u0131 ile g\u00f6sterildi. Obstr\u00fcktif HCM\u2019li hastalarda yap\u0131lan bu randomize \u00e7al\u0131\u015fmada, mavacamten kullanan grupta (doi:10.1056\/NEJMoa2002329):<\/p>\n rapor edildi. Yani ila\u00e7 yaln\u0131zca say\u0131sal parametreleri de\u011fil, hastalar\u0131n g\u00fcnl\u00fck ya\u015fam performans\u0131n\u0131 ve hissettikleri y\u00fck\u00fc<\/strong> de do\u011frudan etkiliyor.<\/p>\n Uzun d\u00f6nem g\u00fcvenlilik ve etkinlik i\u00e7in tasarlanan MAVA-LTE gibi uzatma \u00e7al\u0131\u015fmalar\u0131nda ise, ejeksiyon fraksiyonundaki de\u011fi\u015fimler yak\u0131ndan izlenerek doz ayarlamalar\u0131n\u0131n yap\u0131labildi\u011fi ve etkinli\u011fin s\u00fcrd\u00fcr\u00fclebildi\u011fi g\u00f6sterildi (doi:10.1161\/CIRCULATIONAHA.121.056323). Bu veriler, mavacamten\u2019in uzun soluklu bir tedavi se\u00e7ene\u011fi olabilece\u011fine<\/strong> i\u015faret ediyor.<\/p>\n Mavacamten s\u00f6z konusu oldu\u011funda en \u00f6nemli noktalardan biri, etkinlik\u2013g\u00fcvenlilik dengesinin hassas olmas\u0131<\/strong>. Kardiyak miyozini bask\u0131larken kontraktilitenin gere\u011finden fazla azalmas\u0131, sol ventrik\u00fcl ejeksiyon fraksiyonunda d\u00fc\u015f\u00fc\u015fe neden olabiliyor (doi:10.1161\/CIRCULATIONAHA.121.056323).<\/p>\n Bu y\u00fczden klinik pratikte:<\/p>\n olmazsa olmaz kabul ediliyor. Uygun hasta se\u00e7imi ve yak\u0131n takip ile yan etkilerin y\u00f6netilebilir<\/strong> oldu\u011fu, pek \u00e7ok merkezde cerrahi septal miyektomi veya alkol septal ablasyona farmakolojik bir alternatif<\/strong> sundu\u011fu bildiriliyor (doi:10.1161\/CIRCULATIONAHA.121.056323; doi:10.1056\/NEJMoa2002329).<\/p>\n Mavacamten, yaln\u0131zca obstr\u00fcktif HCM i\u00e7in yeni bir tedavi sunmakla kalm\u0131yor; kontraktiliteyi mod\u00fcle eden k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lar \u00e7a\u011f\u0131n\u0131n<\/strong> da ba\u015flang\u0131c\u0131 olarak g\u00f6r\u00fcl\u00fcyor. Devam eden \u00e7al\u0131\u015fmalar, HCM d\u0131\u015f\u0131ndaki kalp yetmezli\u011fi fenotiplerinde, farkl\u0131 genetik varyantlarda ve non-obstr\u00fcktif HCM gibi alt gruplarda bu s\u0131n\u0131f ila\u00e7lar\u0131n rol\u00fcn\u00fc ara\u015ft\u0131r\u0131yor (doi:10.1161\/CIRCRESAHA.120.317105).<\/p>\n \u00d6n\u00fcm\u00fczdeki y\u0131llarda:<\/p>\n g\u00fcndelik kardiyoloji prati\u011finin par\u00e7as\u0131 haline gelebilir. Mavacamten bu a\u00e7\u0131dan, kalp yetmezli\u011fini yaln\u0131zca \u201cpompa yetmezli\u011fi\u201d de\u011fil, molek\u00fcler bir tasar\u0131m problemi<\/strong> olarak ele alan yeni bak\u0131\u015f a\u00e7\u0131s\u0131n\u0131n sembol molek\u00fcllerinden biri olmaya aday.<\/p>\n Mavacamten, \u00f6ncelikle obstr\u00fcktif hipertrofik kardiyomiyopati (HCM)<\/strong> tedavisi i\u00e7in geli\u015ftirilmi\u015f bir kardiyak miyozin inhibit\u00f6r\u00fcd\u00fcr. Bu hasta grubunda sol ventrik\u00fcl \u00e7\u0131k\u0131\u015f yolundaki obstr\u00fcksiyonu ve semptomlar\u0131 azaltmak amac\u0131yla kullan\u0131l\u0131r (doi:10.1056\/NEJMoa2002329).<\/p>\n Beta blokerler, kalp h\u0131z\u0131n\u0131 ve kas\u0131lma g\u00fcc\u00fcn\u00fc azaltmak i\u00e7in adrenerjik resept\u00f6rleri<\/strong> hedef al\u0131r. Mavacamten ise do\u011frudan kardiyak miyozinin ATPaz aktivitesini inhibe ederek<\/strong> a\u015f\u0131r\u0131 kas\u0131lmay\u0131 azalt\u0131r. Yani sinyal yolaklar\u0131 yerine, kalp kas\u0131n\u0131n \u201cmotor proteinine\u201d etki eder (doi:10.1161\/CIRCRESAHA.120.317105).<\/p>\n Temel ama\u00e7 kalbi zay\u0131flatmak de\u011fil, patolojik olarak artm\u0131\u015f kontraktiliteyi fizyolojik s\u0131n\u0131rlara \u00e7ekmektir<\/strong>. Ancak baz\u0131 hastalarda ejeksiyon fraksiyonunda istenmeyen d\u00fc\u015f\u00fc\u015fler g\u00f6r\u00fclebilece\u011fi i\u00e7in d\u00fczenli ekokardiyografik takip ve doz ayarlamas\u0131 \u015fartt\u0131r (doi:10.1161\/CIRCULATIONAHA.121.056323).<\/p>\n \u0130leri derecede d\u00fc\u015f\u00fck ejeksiyon fraksiyonu olan, belirgin aritmi riski ta\u015f\u0131yan veya ciddi ek hastal\u0131klar\u0131 bulunan bireylerde mavacamten kullan\u0131m\u0131 dikkatle de\u011ferlendirilmelidir. Tedavi karar\u0131, mutlaka deneyimli bir kardiyoloji uzman\u0131<\/strong> taraf\u0131ndan, g\u00fcncel k\u0131lavuzlar ve klinik \u00e7al\u0131\u015fmalar \u0131\u015f\u0131\u011f\u0131nda verilmelidir (doi:10.1056\/NEJMoa2002329).<\/p>\n Uzun d\u00f6nem veriler hala toplanmakla birlikte, mevcut uzatma \u00e7al\u0131\u015fmalar\u0131nda, dikkatli doz titrasyonu ve d\u00fczenli g\u00f6r\u00fcnt\u00fcleme<\/strong> ile etkinlik ve g\u00fcvenlilik dengesinin s\u00fcrd\u00fcr\u00fclebildi\u011fi g\u00f6sterilmi\u015ftir (doi:10.1161\/CIRCULATIONAHA.121.056323; doi:10.1161\/CIRCRESAHA.120.317105). Yeni veriler geldik\u00e7e, mavacamten\u2019in kalp yetmezli\u011fi tedavisindeki yeri daha da netle\u015fecektir.<\/p>\n doi:10.1056\/NEJMoa2002329 Mavacamten, obstr\u00fcktif hipertrofik kardiyomiyopati (HCM) tedavisinde kardiyak miyozini do\u011frudan hedefleyen yenilik\u00e7i bir k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7t\u0131r. Etki mekanizmas\u0131, EXPLORER-HCM klinik verileri ve kalp yetmezli\u011fi tedavisinde neden bu kadar konu\u015fuldu\u011funu detayl\u0131 inceleyin.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[122],"tags":[789,784,787,786,790,788,783,785],"class_list":["post-10236","post","type-post","status-publish","format-standard","hentry","category-molekul","tag-explorer-hcm","tag-hipertrofik-kardiyomiyopati","tag-kalp-yetmezligi-tedavisi","tag-kardiyak-miyozin-inhibitoru","tag-kardiyoloji","tag-kucuk-molekul-ilac","tag-mavacamten","tag-obstruktif-hcm"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10236","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10236"}],"version-history":[{"count":1,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10236\/revisions"}],"predecessor-version":[{"id":10237,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10236\/revisions\/10237"}],"wp:attachment":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10236"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10236"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10236"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Etki Mekanizmas\u0131: K\u00fc\u00e7\u00fck Molek\u00fcl, B\u00fcy\u00fck Hedef \u2013 Kardiyak Miyozin<\/h2>\n
\n
Klinik Kan\u0131tlar: EXPLORER-HCM ve Uzun D\u00f6nem Veriler<\/h2>\n
\n
G\u00fcvenlilik Profili: \u0130nce Ayar Gerektiren K\u00fc\u00e7\u00fck Molek\u00fcl<\/h2>\n
\n
Gelecek Perspektifi: Miyozin Hedefli K\u00fc\u00e7\u00fck Molek\u00fcllerin Yeni \u00c7a\u011f\u0131<\/h2>\n
\n
S\u0131k Sorulan Sorular: Mavacamten Hakk\u0131nda Merak Edilenler<\/h2>\n
1. Mavacamten hangi hastal\u0131k i\u00e7in onay alm\u0131\u015f bir k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7t\u0131r?<\/h3>\n
2. Mavacamten, beta blokerlerden nas\u0131l farkl\u0131 \u00e7al\u0131\u015f\u0131r?<\/h3>\n
3. Mavacamten kalp kas\u0131n\u0131 \u201czay\u0131flat\u0131r\u201d m\u0131?<\/h3>\n
4. Mavacamten herkese uygun mu, kimler kullanamaz?<\/h3>\n
5. Mavacamten\u2019in uzun d\u00f6nem etkileri biliniyor mu?<\/h3>\n
Kaynaklar<\/h2>\n
\ndoi:10.1161\/CIRCULATIONAHA.121.056323
\ndoi:10.1161\/CIRCRESAHA.120.317105<\/p>\n","protected":false},"excerpt":{"rendered":"